BBOT vs. CANC

Last updated Jun 4, 2026

BBOT (BridgeBio Oncology Therapeutics, Inc) is a stock, while CANC (Tema Oncology ETF) is Health & Biotech Equities fund actively managed by Tema. At a 0.35 correlation, their price movements are largely independent.

Performance

BBOT vs. CANC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BridgeBio Oncology Therapeutics, Inc (BBOT) and Tema Oncology ETF (CANC). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BBOT achieves a -35.86% return, which is significantly lower than CANC's 4.82% return.

BBOT

• 1D: -2.90%
• 1M: -5.08%
• YTD: -35.86%
• 6M: -27.46%
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

CANC

• 1D: 0.08%
• 1M: -3.73%
• YTD: 4.82%
• 6M: 3.86%
• 1Y: 47.37%
• 3Y*: 107.76%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

BBOT vs. CANC - Yearly Performance Comparison

	2026 (YTD)	2025
BBOT BridgeBio Oncology Therapeutics, Inc	-35.86%	29.74%
CANC Tema Oncology ETF	4.82%	35.85%

Correlation

The correlation between BBOT and CANC is 0.35, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (All Time) Calculated using the full available price history since Aug 13, 2025	0.35

Return for Risk

BBOT vs. CANC — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CANC

CANC Risk / Return Rank: 69
CANC Sharpe Ratio Rank: 61
CANC Sortino Ratio Rank: 64
CANC Omega Ratio Rank: 54
CANC Calmar Ratio Rank: 90
CANC Martin Ratio Rank: 77

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

BBOT vs. CANC - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BridgeBio Oncology Therapeutics, Inc (BBOT) and Tema Oncology ETF (CANC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	BBOT	CANC	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	—	2.06	—
Sharpe Ratio (All Time) Calculated using the full available price history	-0.29	-0.04	-0.25

Drawdowns

BBOT vs. CANC - Drawdown Comparison

The maximum BBOT drawdown since its inception was -44.21%, smaller than the maximum CANC drawdown of -97.53%. Use the drawdown chart below to compare losses from any high point for BBOT and CANC.

Drawdown Indicators

	BBOT	CANC	Difference
Max Drawdown Largest peak-to-trough decline	-44.21%	-97.53%	+53.32%
Max Drawdown (1Y) Largest decline over 1 year	—	-8.67%	—
Max Drawdown (3Y) Largest decline over 3 years	—	-30.27%	—
Current Drawdown Current decline from peak	-41.51%	-56.55%	+15.04%
Average Drawdown Average peak-to-trough decline	-19.09%	-73.19%	+54.10%
Ulcer Index Depth and duration of drawdowns from previous peaks	—	3.25%	—

Volatility

Volatility by Period

	BBOT	CANC	Difference
Volatility (1M) Calculated over the trailing 1-month period	—	6.26%	—
Volatility (6M) Calculated over the trailing 6-month period	—	16.69%	—
Volatility (1Y) Calculated over the trailing 1-year period	71.16%	23.11%	+48.05%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	71.16%	280.27%	-209.11%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	71.16%	280.27%	-209.11%

Dividends

BBOT vs. CANC - Dividend Comparison

BBOT has not paid dividends to shareholders, while CANC's dividend yield for the trailing twelve months is around 0.05%.

Position	TTM	2025	2024	2023
BBOT BridgeBio Oncology Therapeutics, Inc	0.00%	0.00%	0.00%	0.00%
CANC Tema Oncology ETF	0.05%	0.06%	3.00%	0.56%

Frequently Asked Questions

Can I hold both BBOT and CANC in my portfolio?

BBOT and CANC have a correlation of 0.35, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.